| Species |
Human/Cynomolgus |
| Protein Construction |
Activin RIIB/ACVR2B [Ser19-Thr137 (Human) / Ser40-Thr158 (Cynomolgus)]
Accession # Q13705-1 (Human) / XP_045242398.1 (Cynomolgus) |
hFc |
Avi |
| N-term |
|
C-term |
|
| Conjugate |
Biotin |
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human Activin A, No Tag at 1μg/ml (100μl/well) on the plate can bind Activin RIIB/ACVR2B hFc Chimera[Biotin], Avi, Human/Cynomolgus. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
41.41 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 55-70 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
ActRIIB (activin receptor type-2B) is an activin receptor subtype constitutively expressed in the whole body, playing a role in cellular proliferation, differentiation, and metabolism. For its various physiological activities, ActRIIB interacts with activin and multiple other ligands including myostatin (MSTN), growth differentiation factor 11 (GDF11), and bone morphogenetic protein 9 (BMP9). |
| Synonyms |
Activin receptor type-2B; ACVR2B; Activin RIIB |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
